Research programme: gastrointestinal disorder and autoimmune disorder therapeutics - Genexine

Drug Profile

Research programme: gastrointestinal disorder and autoimmune disorder therapeutics - Genexine

Alternative Names: GX-G8; GX-P2

Latest Information Update: 06 May 2016

Price : $50

At a glance

  • Originator Genexine
  • Class Proteins
  • Mechanism of Action CD274 antigen inhibitors; Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diarrhoea; Inflammatory bowel diseases; Psoriasis; Short bowel syndrome

Most Recent Events

  • 06 May 2016 Preclinical trials in Psoriasis in South Korea (unspecified route) before May 2016
  • 04 Dec 2015 Preclinical trials in Short bowel syndrome in South Korea (unspecified route)
  • 04 Dec 2015 Preclinical trials in Diarrhoea (Chemotherapy-induced) in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top